BCL2 and lung cancer: Antisense oligonucleotides: Lipid nanoparticles loaded with a gapmer antisense oligonucleotide against Bcl-2 (G3139-GAP) were developed to deliver a modified antisense oligonucleotide targeting the Bcl-2 gene, crucial for lung cancer treatment.